Top

Published in:

01-08-2010 | Invited Commentary

Is ALDH1 a good method for definition of breast cancer stem cells?

Authors: Veronique Neumeister, David Rimm

Published in: Breast Cancer Research and Treatment | Issue 1/2010

Excerpt

In a series of recent studies, in addition to CD44 and CD24 expression, ALDH1 has been described to play a crucial role in identification of putative cancer stem cells (CSCs) and/or potential cancer initiating cells in breast cancer. The initial description of this observation was from the Max Wicha group in 2007 where Ginestier et al. describe the use of an antibody to ALDH1 as a method to identify CSCs by immunohistochemistry (IHC). Since then, many investigators have attempted to use this marker on breast cancer tissue. Here, in this issue of the journal, the work of the Badve group does a series of IHC experiments with ALDH1, but finds a unique result. …

Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S et al (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5):555–567CrossRefPubMed

Sansone P, Storci G, Giovannini C, Pandolfi S, Pianetti S, Taffurelli M, Santini D, Ceccarelli C, Chieco P, Bonafe M (2007) p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres. Stem Cells 25(3):807–815CrossRefPubMed

Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R Jr, Badve S, Nakshatri H (2006) CD44+/CD24-breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8(5):R59CrossRefPubMed

Vassilopoulos A, Wang RH, Petrovas C, Ambrozak D, Koup R, Deng CX (2008) Identification and characterization of cancer initiating cells from BRCA1 related mammary tumors using markers for normal mammary stem cells. Int J Biol Sci 4(3):133–142PubMed

Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L (2008) Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 10(1):R10CrossRefPubMed

Morimoto K, Kim SJ, Tanei T, Shimazu K, Tanji Y, Taguchi T, Tamaki Y, Terada N, Noguchi S (2009) Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci 100(6):1062–1068CrossRefPubMed

Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S (2009) Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 15(12):4234–4241CrossRefPubMed

Duester G (2000) Families of retinoid dehydrogenases regulating vitamin A function: production of visual pigment and retinoic acid. Eur J Biochem 267(14):4315–4324CrossRefPubMed

Simeone AM, Tari AM (2004) How retinoids regulate breast cancer cell proliferation and apoptosis. Cell Mol Life Sci 61(12):1475–1484CrossRefPubMed

10.

Visus C, Ito D, Amoscato A, Maciejewska-Franczak M, Abdelsalem A, Dhir R, Shin DM, Donnenberg VS, Whiteside TL, DeLeo AB (2007) Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. Cancer Res 67(21):10538–10545CrossRefPubMed

11.

Trimboli AJ, Cantemir-Stone CZ, Li F, Wallace JA, Merchant A, Creasap N, Thompson JC, Caserta E, Wang H, Chong JL et al (2009) Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 461(7267):1084–1091CrossRefPubMed

Title: Is ALDH1 a good method for definition of breast cancer stem cells?
Authors: Veronique Neumeister
David Rimm
Publication date: 01-08-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0656-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2010

Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer

Diagnosing breast lesions by fine needle aspiration cytology or core biopsy: which is better?

Comparative disease pattern of a patient with a novel BRCA2 truncation and knockout models for BRCA2

Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells

Five common single nucleotide polymorphisms in the PALB2 gene and susceptibility to breast cancer in eastern Chinese population

Associations between XPD polymorphisms and risk of breast cancer: a meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer